跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 29 条关于
“tixagavimab/cilgavimab”
全部
29
临床试验
14
药物
5
机构
0
资讯
10
去年
Invivyd's Pemgarda Shows Continued Neutralizing Activity Against SARS-CoV-2 Variant XEC
去年
FDA Revokes Emergency Use Authorizations for COVID-19 Antibody Treatments Evusheld and REGEN-COV
4年前
FDA Authorizes AstraZeneca's Evusheld for COVID-19 Prevention in Immunocompromised Individuals
2年前
FDA Revokes Emergency Use Authorization for Evusheld Due to Variant Ineffectiveness
去年
AZ's Antibody First to Be Cleared by FDA for COVID Prevention
去年
FDA Revokes Emergency Use Authorizations for Four COVID-19 Monoclonal Antibody Products
去年
FDA Limits GSK's Xevudy Authorization Due to BA.2 Variant Concerns
11个月前
INOVIO's DNA-Encoded Antibody Platform Achieves 72-Week Sustained Expression in Phase 1 Trial
3年前
FDA Restricts Emergency Use Authorization for AstraZeneca's Evusheld in the US
去年
INOVIO's DNA-Encoded Monoclonal Antibodies Show Durable 72-Week Expression Without Immune Rejection in COVID-19 Trial